Overview
InterVenn Biosciences offers GlycoVision™, an AI-powered glycoproteomics platform using LC-MS/MS for high-throughput biomarker discovery from serum or plasma samples. The platform enables site-specific protein glycosylation analysis for precision medicine applications in oncology, diagnostics, and drug development. Key products include the GlycoKnow™ Ovarian cancer liquid biopsy test, with partnerships expanding clinical workflows and global lab facilities.
Frequently asked questions
- What is InterVenn's core technology platform?
- GlycoVision™ integrates LC-MS/MS with AI/ML for high-resolution glycoproteome analysis, identifying glycopeptide biomarkers with >99% concordance to expert analysis.
- What specific diagnostic products does InterVenn offer?
- GlycoKnow™ Ovarian is a blood-based liquid biopsy test that distinguishes ovarian cancer from benign pelvic masses, offered as a laboratory-developed test.
- What are InterVenn's geographic capabilities?
- InterVenn operates facilities in the US (California, South San Francisco), Asia-Pacific (Kuala Lumpur, Philippines), and Australia for clinical research, software development, and technical support.